)
Definium Therapeutics (DFTX) investor relations material
Definium Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.DT120 clinical progress and regulatory plans
Proprietary ODT form of LSD; three positive pivotal readouts over the summer across GAD and MDD, with management citing the largest pivotal-study effect in each indication for a single dose.
Fourth pivotal study, the second in MDD, expected to read out in 2027; NDA filing targeted for H1 2027.
Filing routes under consideration include joint GAD/MDD submission, GAD first followed by an MDD sNDA, or staggered submissions potentially timed for a joint launch; pre-NDA meeting planned for Q4.
Breakthrough Therapy designation for both programs; frequent FDA dialogue and NDA compilation underway after pivotal work begun in Jan 2022.
Dose profile and care model
Retreatment is expected when symptoms return; the nine-month extension allowed up to four open-label doses for return of moderate-or-worse symptoms.
Data through six months showed ~25% with lasting benefit after one dose and ~one-third requiring a second; most patients appeared to fall in the one-to-three-dose range.
Trial observation averaged six hours, converging from a five-to-eight-hour range; one person was typically in the room with the patient, with a second staffer monitoring by video.
Most trial monitors were licensed clinical social workers; more open-label data expected in the near future.
Single dose is 100 mcg; management said accrued supply is more than sufficient for NDA filing needs.
Market and launch opportunity
Estimated U.S. population with GAD or MDD is 50m; management’s treatment funnel implies ~4m patients eligible for a step-three therapy after diagnosis, treatment and multiple drug failures.
SPRAVATO was cited as an analog at ~$2bn annual revenue and $30k-$70k annual pricing, with a ~$50k midpoint; it can involve up to 56 doses a year versus a few expected for DT120.
Management sees potential to launch DT120 for both GAD and MDD, and described treatment centers as integrating multiple interventions and adaptable to new modalities.
Management said Usona’s psilocybin filing would not set a negative pricing precedent, citing distinct programs and a focus on resourcing responsible delivery.
- Positive DT120 Phase 3 results support a targeted 1H 2027 NDA filing.DFTX
Corporate presentation - DT120 targets an H1 2027 NDA; early DT402 findings support continued ASD development.DFTX
Stifel 2026 Healthcare Conference 2026 - Phase 3 DT120 results support an H1 2027 NDA target, with $1.05B projected to fund operations into 2030.DFTX
Q3 2026 - DT120 demonstrated strong efficacy and safety in GAD and MDD, with durable benefits and flexible dosing.DFTX
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - DT120 ODT demonstrated best-in-class efficacy and safety in GAD and MDD, with NDA filing planned for 2027.DFTX
Corporate presentation - DT120 ODT 100 µg achieved rapid, durable efficacy and favorable safety in Phase 3 GAD study.DFTX
Study result - DT120 ODT delivers best-in-class efficacy and safety in GAD and MDD, supporting blockbuster potential.DFTX
Corporate presentation - DT120 ODT showed rapid, robust, and durable efficacy in GAD with strong safety and long-term benefits.DFTX
Study result - Record Phase 3 MDD efficacy, $1.1B cash, and GAD data drive continued pipeline momentum.DFTX
Q2 2026
)
)
)
)
)
)
)
)